hold on , the game is far from over
must read for all longs and shorts, tysabri is precedent case to omontys
I think its main competitor Biogen bought the drug too. Thus AFFY will survive and Omontys will come back!
yeah , takeda is giant, can easily swallow this for 200mn $
I would agree if it was a CEO who cared about the company,shareholders and knew what he was doing
The drugmarket will soon be looking very different with regulations changing...soon this drug will sell for 5% of what it is selling now